NHVA New Hampshire Vaccine Association

AGENDA
AUDIT COMMITTEE MEETING
August 19, 2026
9:00am – 10:00am
Location: Online Zoom Meeting

To attend via Zoom webinar, please register at this link:
https://nhvaccine.org/event/nhva-audit-committee-meeting-august-19-2026/

9:00am-9:05am	**1. Call to Order (M. Harris)** a. Notice of Recording* b. Roll Call
9:05am-9:10am	**2. Review and Accept the April 15, 2026 Meeting Minutes (M. Harris)* – VOTE**
9:10am-9:25am	**3. Review and Recommend FY2026 Audited Financial Statements (Leone, McDonnel & Roberts PA) – VOTE** a. Auditor's Overview of Draft FY2026 Audited Financial Statements* *b. Executive Session with Auditor and Committee Members Only*
9:25am-9:50am	**4. Executive Director Report (P. Miller)** a. CY 2027 Initial Rate Setting Discussion* (P. Miller / L. Walker) b. Unaudited Financial Statements as of July 31, 2026* c. Assessments Received as of August 15, 2026
9:50am-9:55am	**5. Other Business**
9:55am-10:00am	**6. Public Comments (M. Harris)** a. Audit Committee Chair Statement re: Public Commentary During Meetings* b. Public Invited to Speak
10:00am	**7. Call to Adjourn (M. Harris)**

* Indicates an attachment

c/o Helms & Company, Inc. ♦ One Pillsbury Street, Suite 200 ♦ Concord NH 03301 ♦ 603-225-6633 ♦ www.nhvaccine.org

NOTICE OF MEETING RECORDING

The Association is audio and video recording this meeting. The recording will be placed on its website within forty-eight (48) hours after the meeting. Please inform the Board now if you will be recording this meeting by raising your hand or using the chat feature in Zoom.

Updated 08/2025

MINUTES
Audit Committee Meeting
April 15, 2026
9:00 a.m.
Via Zoom Webinar
Presiding Officer: Morgan Harris, Chair, Audit Committee

A meeting of the Audit Committee of the Board of Directors of the New Hampshire Vaccine Association (NHVA) with a quorum present was held via Zoom Webinar.

Ms. Harris, Chair, called the meeting to order at 9:00 a.m.

1. Welcome and Introductions

Attendance – The following individuals attended the meeting:

Committee Members:	Administrative Staff
Morgan Harris, NHID, Chair	Patrick Miller, Helms & Company
Adriane Burke, NH DHHS	Erin Meagher, Helms & Company
Marie Doyle, HPHC	Victoria Bram, Helms & Company
	Members of the Public
	Megan Heddy, Concord, NH

Ms. Harris opened the meeting by taking a roll call for attendance purposes.

Committee Member	*Present*	*Excused*
Adriane Burke	*X*	
Morgan Harris	*X*	
Marie Doyle	*X*	

Ms. Harris recited NHVA's *Notice of Recording* statement and asked if any members of the public were recording the meeting to please indicate so by raising their virtual hand. No member of the public indicated they were recording.

2. Review and Acceptance of August 20, 2025, Meeting Minutes

Ms. Harris asked the Committee if any members had any questions or comments about the August 20, 2025, meeting minutes. Hearing no questions, she asked for a motion.

VOTE RECORDED: *On a motion by Ms. Burke, seconded by Ms. Doyle, by roll call vote, it was unanimously*
VOTED: *To accept the August 20, 2025, Audit Committee meeting minutes as presented.*

Committee Member	*Yes*	*Abstain*
Morgan Harris, NHID, Chair	*X*	
Adriane Burke, NH DHHS	*X*	
Marie Doyle, HPHC	*X*	

3. Executive Director Report

a. FY2026 Auditor Proposal Review and Recommendation.
Mr. Miller presented the proposal from Leone, McDonnell, and Roberts, PA for audit services for FY2026. He explained that this would be the second year of the firm's services, and that the audit went very

smoothly last year. The firm proposed a 3.2% adjustment over last year's fees. There were no questions from the Committee.

VOTE RECORDED: *On a motion by Ms. Burke, seconded by Ms. Doyle, by roll call, it was unanimously*

VOTED: *To recommend to the full Board of Directors at the June 17, 2026 Board meeting to approve the FY2026 Auditor proposal from Leone, McDonnell and Roberts, PA.*

Committee Member	*Yes*	*Abstain*
Morgan Harris, NHID, Chair	*X*	
Adriane Burke, NH DHHS	*X*	
Marie Doyle, HPHC	*X*	

b. FY2027 Administrative Budget Review & Recommendation.

Mr. Miller reviewed the line items in the proposed FY2027 budget. All budget items remain level except for a proposed reduction in director and officer insurance fees and a proposed increase in the auditor fees. There were no questions from the Committee.

VOTE RECORDED: *On a motion by Ms. Doyle, seconded by Ms. Burke, by roll call, it was unanimously*

VOTED: *To recommend to the full Board of Directors at the June 17, 2026 Board meeting to adopt the FY2027 Administrative Budget as presented.*

Committee Member	*Yes*	*Abstain*
Morgan Harris, NHID, Chair	*X*	
Adriane Burke, NH DHHS	*X*	
Marie Doyle, HPHC	*X*	

c. Unaudited Financial Statements as of March 31, 2026.

Mr. Miller reviewed the unaudited financial statements. Revenues for the first three quarters are tracking well, and administrative expenses remain under budget for another month, primarily due to lack of need for legal services. Ms. Harris stated that she was pleased with the administrative budget performance. There were no questions from the Committee. Mr. Miller indicated that a vote was not necessary.

4. Other Business

The Committee identified no further business to discuss.

5. Public Comment

Ms. Harris asked if any member of the public would like to speak. No members asked to speak.

6. Executive Session

Ms. Harris asked the Committee if there was any need for an Executive Session. The Committee members indicated an Executive Session was not necessary.

7. Adjournment

Having no other business, Ms. Harris asked for a motion to adjourn.

VOTE RECORDED: *On a motion by Ms. Burke seconded by Ms. Doyle by roll call, it was unanimously*

VOTED: *To adjourn the Audit Committee meeting at 9:18 a.m.*

Committee Member	*Yes*	*Abstain*
Morgan Harris, NHID, Chair	*X*	
Adriane Burke, NH DHHS	*X*	
Marie Doyle, HPHC	*X*	

Respectfully submitted by
Patrick Miller, Helms & Company, Inc.
April 15, 2026

\# # #

NEW HAMPSHIRE VACCINE ASSOCIATION

FOR THE YEARS ENDED
JUNE 30, 2026 AND 2025
AND
INDEPENDENT AUDITORS' REPORT

NEW HAMPSHIRE VACCINE ASSOCIATION

FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2026 AND 2025

TABLE OF CONTENTS

INDEPENDENT AUDITORS' REPORT

To the Board of Directors of
New Hampshire Vaccine Association

Opinion

We have audited the accompanying financial statements of New Hampshire Vaccine Association (a nonprofit organization), which comprise the statements of financial position as of June 30, 2026 and 2025, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of New Hampshire Vaccine Association as of June 30, 2026 and 2025, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of New Hampshire Vaccine Association and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about New Hampshire Vaccine Association's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of New Hampshire Vaccine Association's internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.

- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about New Hampshire Vaccine Association's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Dover, New Hampshire
August 5, 2026

<u>**NEW HAMPSHIRE VACCINE ASSOCIATION**</u>

STATEMENTS OF FINANCIAL POSITION
JUNE 30, 2026 AND 2025

ASSETS

	2026	2025
CURRENT ASSETS		
Cash and cash equivalents	$ 6,786,728	$ 3,989,278
Prepaid expenses	1,960	2,523
Total current assets	6,788,688	3,991,801
NONCURRENT ASSETS		
Investments	3,268,106	3,898,764
Total noncurrent assets	3,268,106	3,898,764
Total assets	$ 10,056,794	$ 7,890,565

LIABILITIES AND NET ASSETS

	2026	2025
CURRENT LIABILITIES		
Accounts payable	$ -	$ 3,135
Total liabilities	-	3,135
NET ASSETS		
Without donor restrictions		
Board Designated - Reserved for Rate Stabilization	5,000,000	5,000,000
Board Designated - Administrative Reserves	250,000	250,000
With donor restrictions	4,806,794	2,637,430
Total net assets	10,056,794	7,887,430
Total liabilities and net assets	$ 10,056,794	$ 7,890,565

See Notes to Financial Statements

NEW HAMPSHIRE VACCINE ASSOCIATION

STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2026

	Without Donor Restrictions	With Donor Restrictions	Total
REVENUES, GAINS AND OTHER PUBLIC SUPPORT			
Assessment income	$ -	$ 24,364,406	$ 24,364,406
Interest of late assessments	-	1,139	1,139
Bank and sweep interest	-	599,103	599,103
Return on investments, net	-	166,403	166,403
Less refunds and allowances	-	(52,737)	(52,737)
Net assets released from restrictions	22,908,950	(22,908,950)	-
Total revenues, gains and other public support	22,908,950	2,169,364	25,078,314
FUNCTIONAL EXPENSES			
Program	22,756,655	-	22,756,655
General and administrative	152,295	-	152,295
Total functional expenses	22,908,950	-	22,908,950
CHANGES IN NET ASSETS	-	2,169,364	2,169,364
NET ASSETS, BEGINNING OF YEAR	5,250,000	2,637,430	7,887,430
NET ASSETS, END OF YEAR	$ 5,250,000	$ 4,806,794	$ 10,056,794

See Notes to Financial Statements

NEW HAMPSHIRE VACCINE ASSOCIATION

STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2025

	Without Donor Restrictions	With Donor Restrictions	Total
REVENUES, GAINS AND OTHER PUBLIC SUPPORT			
Assessment income	$ -	$ 24,208,126	$ 24,208,126
Interest of late assessments	-	6,013	6,013
Bank and sweep interest	-	611,597	611,597
Return on investments, net	-	246,031	246,031
Less refunds and allowances	-	(5,000)	(5,000)
Net assets released from restrictions	23,207,504	(23,207,504)	-
Total revenues, gains and other public support	23,207,504	1,859,263	25,066,767
FUNCTIONAL EXPENSES			
Program	23,046,587	-	23,046,587
General and administrative	160,917	-	160,917
Total functional expenses	23,207,504	-	23,207,504
CHANGES IN NET ASSETS	-	1,859,263	1,859,263
NET ASSETS, BEGINNING OF YEAR	5,250,000	778,167	6,028,167
NET ASSETS, END OF YEAR	$ 5,250,000	$ 2,637,430	$ 7,887,430

See Notes to Financial Statements

NEW HAMPSHIRE VACCINE ASSOCIATION

STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED JUNE 30, 2026

	PROGRAM	GENERAL AND ADMINISTRATIVE	TOTAL
Remittance to State of NH	$ 22,756,655	$ -	$ 22,756,655
Administrative services	-	129,300	129,300
Accounting fees	-	11,070	11,070
Legal fees	-	6,129	6,129
Insurance	-	3,360	3,360
Board meeting expenses	-	990	990
Website	-	871	871
Stationary and printing	-	500	500
License and fees	-	75	75
Total functional expenses	$ 22,756,655	$ 152,295	$ 22,908,950

See Notes to Financial Statements

NEW HAMPSHIRE VACCINE ASSOCIATION

STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED JUNE 30, 2025

	PROGRAM	GENERAL AND ADMINISTRATIVE	TOTAL
Remittance to State of NH	$ 23,046,587	$ -	$ 23,046,587
Administrative services	-	117,552	117,552
Legal fees	-	26,297	26,297
Accounting fees	-	11,530	11,530
Insurance	-	3,360	3,360
Board meeting expenses	-	1,230	1,230
Website	-	486	486
License and fees	-	233	233
Stationary and printing	-	229	229
Total functional expenses	$ 23,046,587	$ 160,917	$ 23,207,504

See Notes to Financial Statements

NEW HAMPSHIRE VACCINE ASSOCIATION

STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30, 2026 AND 2025

	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Changes in net assets	$ 2,169,364	$ 1,859,263
Adjustments to reconcile changes in net assets to net cash from operating activities:		
Gain on sale of investments	(11,650)	(5,620)
Unrealized gain on investments	(104,344)	(185,358)
(Increase) decrease in assets:		
Prepaid expenses	563	(563)
Increase (decrease) in liabilities:		
Accounts payable	(3,135)	3,055
NET CASH PROVIDED BY OPERATING ACTIVITIES	2,050,798	1,670,777
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of investments	(232,198)	(49,432)
Proceeds from sale and maturities of investments	978,850	766,380
NET CASH PROVIDED BY INVESTING ACTIVITIES	746,652	716,948
NET INCREASE IN CASH AND CASH EQUIVALENTS	2,797,450	2,387,725
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	3,989,278	1,601,553
CASH AND CASH EQUIVALENTS, END OF YEAR	$ 6,786,728	$ 3,989,278

See Notes to Financial Statements

NEW HAMPSHIRE VACCINE ASSOCIATION

NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2026 AND 2025

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General

New Hampshire Vaccine Association (the "Association") is a nonprofit corporation established pursuant to Chapter 126-Q of the New Hampshire Revised Statutes Annotated. The Association was formed to assess certain entities for a portion of the cost of vaccines provided for children in New Hampshire. The Association accomplishes its mission by assessing "assessable entities", as defined by RSA 126-Q:1, II. That definition encompasses all insurers, all government health benefit plans and essentially all third-party administrators administrating health benefits for any child covered life in New Hampshire. The Association remits funds to the State of New Hampshire so that the NH Department of Health and Human Services is able to purchase and distribute, without charge to health care providers in the State of New Hampshire, all federally recommended childhood vaccines.

Basis of Accounting

The financial statements of the Association have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Basis of Presentation

The financial statements of the Association have been prepared in accordance with U.S. Generally Accepted Accounting Principles (US GAAP), which require the Association to report information regarding its financial position and activities according to the following net asset classifications:

> Net assets without donor restrictions – Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Association. These net assets may be used at the discretion of the Association's management and board of directors.
>
> Net assets with donor restrictions – Net assets subject to stipulations imposed by law. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Association or by passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity. The Association does not have any net assets with perpetual donor restrictions.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments
Cash, accounts receivable, accounts payable, accrued expenses and other liabilities are carried in the financial statements at amounts which approximate fair value. The fair values determined for financial instruments are estimates, which for certain accounts may differ significantly from the amounts that could be realized upon immediate liquidations.

Cash and Cash Equivalents
The Association considers all short-term highly liquid investments with original maturities of three months or less to be cash equivalents with the exception of temporary cash, money market funds, and short-term investments held in the investment account.

Investments
The Association carries investments in debt and equity securities at their fair values in the Statement of Financial Position. Unrealized gains and losses are included in the change in net assets in the accompanying Statement of Activities. Investments includes any accrued investment income reportable by the broker managing the funds, as this income has been earned and not yet received.

Assessments Receivable
Assessments receivable are stated at the amount the Association expects to collect from covered lives self-reported by assessable entities. The Association evaluates collectability by considering factors such as historical experience, the age of the accounts receivable balance, current economic conditions, and other circumstances, which may affect an entity's ability to pay. Past due receivables are written off at management's discretion using the direct write off method; this is not considered a departure from accounting principles generally accepted in the United States because the effects of the direct write off method approximate those of the allowance method. The Association charges a late fee at a rate of 18% per annum (about 1.5% monthly) on all past due assessments until paid in full or written off as uncollectible.

Assessment Revenue
Assessable entities self-report the number of covered lives for each month of the quarter. The assessment is due 45 days after the close of the preceding quarter. Assessment revenue is recognized as an increase in donor restricted net assets at that time.

While RSA-126Q requires the Association to submit an annual covered lives report to the Commissioner of Insurance, neither the statute nor the Plan of Operation provide any requirement for the Association to identify or verify the self-reported covered lives of assessable entities. Accordingly, revenue is recognized as self-reported by the assessable entities. Any subsequent adjustments in covered lives reported to the Association are treated as an increase or decrease in assessment revenue at that time.

Expense Allocation

Due to the limited purpose of the Association's mandate as defined in RSA 126-Q, the remittance of assessments to the State comprises the entirety of program activities. Expenses have been classified in the Statement of Functional Expenses based on the nature and function of the expense. The remittance is reflected on the financial statements as a release of net assets with donor restrictions. All remaining expenses are related to general and administrative activities.

Income Tax Status

The Association was organized as a nonprofit organization under RSA 292. On January 20, 2004, the Internal Revenue Service ruled that the Association was a nonprofit 501(c)(3) organization, furthermore that it was not a private foundation within the meaning of Internal Revenue Code Section 509(a). Accordingly, the Association has not made any provision for income taxes.

In addition, the Internal Revenue Service ruled that the Association met the requirements set forth in Revenue Procedure 95-48, 1995-2 CB 418 section 4.02(b) and 4.03. Therefore, the Association is not required to file Form 990 annually.

For the years ended June 30, 2026 and 2025, management has evaluated its tax positions in accordance with financial accounting standards board (FASB) accounting standards codification (ASC) 740-10, Accounting for Uncertain Tax Positions. This evaluation includes consideration that the Association is operating in compliance with its tax-exempt status and that there are no matters that would create taxable income. The Association's management does not believe they have taken uncertain tax positions, therefore, a liability for income taxes with uncertain tax positions has not been recognized.

Restricted Revenue

RSA 126-Q restricts all revenue, including assessments, interest on late payment of assessments, and investment income. Unexpended revenue is available to support operations and assessment rate stabilization.

2. LIQUIDITY AND AVAILABILITY

None of the cash and cash equivalents are subject to donor or other contractual restrictions that make them unavailable for general expenditure within one year of the balance sheet date. General expenditures include the required remittance to the State of New Hampshire and reasonable and necessary operating costs. Investments set aside for long-term investing are not included in the current resources available for general expenditures. However, these amounts could be drawn upon if needed by the Association.

The Association is substantially supported by assessment income. To manage liquidity, the Association maintains sufficient financial asset balances to satisfy general expenditures as they come due. The Association invests cash in excess of immediate operations in investments to provide a reasonable rate of return to offset the operating expenses and reduce the total cost of the program to insurers.

In determining assessment rates, the Board of Directors includes operating expenses, immunization funding, and reserves. In addition, for the years ended, June 30, 2026 and 2025, the Association designated $5 million of the available unrestricted net assets to provide consistent and stable assessment rates when possible to insurers over time.

3. CONCENTRATIONS

The Association derives nearly all of its revenue from assessable entities with child covered lives in the State of New Hampshire. In addition, assessments from two (2) assessable entities represented 47% and 45% of total assessments for the years ended June 30, 2026 and 2025, respectively.

Given the requirements of RSA 126-Q, the Plan of Operations and the industry within which assessable entities operate, management does not believe the Association is exposed to significant risk from the concentration of assessment revenue, nor from a concentration with a particular assessable entity.

The Association maintains cash deposits with a financial institution that, at times, may exceed federally insured limits. To mitigate this risk, the Association utilizes the IntraFi Cash Service (ICS) through its financial institution, which provides access to expanded FDIC insurance by placing deposits through a network of participating FDIC-insured banks while allowing the Association to maintain a single banking relationship. As a result, substantially all of the Association's cash deposits are federally insured. The Association has not experienced any losses related to its cash deposits.

4. FAIR VALUE MEASUREMENTS

FASB ASC 820, "Fair Value Measurements and Disclosures" establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements), and the lowest priority to unobservable inputs (level 3 measurements).

The three levels of the fair value hierarchy under ASC 820 are described as follows:

Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Association has the ability to access.

Level 2 Inputs to the valuation methodology include:

- quoted prices for similar assets or liabilities in active market;
- quoted prices for identical or similar assets or liabilities in inactive markets;
- inputs other than quoted prices that are observable for the asset or liability;
- inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The following is a description of the valuation methodologies used for investments measured at fair value. There have been no changes in the methodologies used at June 30, 2026 and 2025.

Negotiable certificates of deposit - Valued based on quoted market prices for identical securities in active markets. Fair value reflects current market pricing for the certificates of deposit as of the measurement date.

Money market funds - Valued using quoted market prices or published daily net asset values provided by the fund, representing the price at which shares are transacted at the measurement date.

At June 30, 2026 and 2025, the Association's investments were classified as Level 1 and totaled $3,268,106 and $3,898,764, respectively.

The Association's investments are comprised of money market funds and negotiable certificates of deposit reported at fair value based on quoted market prices (Level 1) as follows:

	June 30, 2026		
	Cost	**Fair Value**	**Unrealized Gain**
Negotiable certificates of deposit	$ 2,721,930	$ 2,747,410	$ 25,480
Money market funds	517,287	517,287	-
Accrued income on investments	3,409	3,409	-
Total investments	$ 3,242,626	$ 3,268,106	$ 25,480

	June 30, 2025		
	Cost	**Fair Value**	**Unrealized Loss**
Negotiable certificates of deposit	$ 3,700,780	$ 3,620,790	$ (79,990)
Money market funds	274,137	274,137	-
Accrued income on investments	3,837	3,837	-
Total investments	$ 3,978,754	$ 3,898,764	$ (79,990)

5. INVESTMENTS

Investments are comprised of the following at June 30, 2026 and 2025.

	2026	**2025**
Negotiable certificates of deposit	$ 2,747,410	$ 3,620,790
Federate government money market	517,287	274,137
Accrued income on investments	3,409	3,837
Total investments	$ 3,268,106	$ 3,898,764

Investments include funds in excess of those necessary for immediate operating needs, including the funds reserved to stabilize assessment rates over time. The return on investments is reported as a change in net assets with donor restrictions in the Statement of Activities.

Investment return is summarized as follows:

	2026	2025
Interest and dividends	$ 64,432	$ 71,965
Net realized and unrealized gains	115,994	190,978
Investment fees	(14,023)	(16,912)
Total	$ 166,403	$ 246,031

6. COMMITMENTS AND CONTINGENCIES

The Association's Plan of Operation provides that assessable entities are assessed a fee based upon the number of covered lives as self-reported. No request for reconsideration of any assessment or refund of payment made shall be considered by the Association with respect to any request which is not filed with the Association, in writing, on or before that date which is six months after the first due date for the corresponding assessment year. The Association's Plan of Operations also states that any overpayments are first considered in connection with the assessment determination for the following year and may, depending upon the cash flow needs of the Association, be spread over multiple years. As a result, the Association does not record a commitment or contingency related to this matter.

In the event of dissolution of the Association, unexpended assessments, including unexpended funds from prior assessments, shall be returned to assessable entities in proportion to their respective assessments paid over the most recent eight (8) quarters preceding the discontinuation of the Association's operations. As there are no plans to dissolve, the Association does not record a commitment or contingency related to this matter.

7. DESIGNATION OF NET ASSETS

Net Assets Without Donor Restrictions

It is the policy of the Board of Directors of the Association to designate appropriate sums of unrestricted net assets to assure adequate cash flow for operations. As of June 30, 2026 and 2025, the board designated balance for this purpose was $250,000. During the year ended, June 30, 2020, the Association reserved $5 million of the available net assets used in setting the assessment rates to provide for consistent and stable assessment rates to insurers over time. The remaining unexpended assessments will be applied to the determination of future assessments, or reasonable and necessary operating costs of the Association.

Net Assets with Donor Restrictions

The Association is a limited purpose entity whose funds are dedicated for remittance to the State of New Hampshire to fund a specified portion of the cost of providing recommended vaccines to children regardless of income or insurance coverage. The Association has collected assessments in excess of amounts required to be remitted to the State.

As of June 30, 2026 and 2025, net assets with donor restrictions is comprised of the following:

	2026	2025
Unexpended assessments		
Available for rate setting	$ 4,806,794	$ 2,637,430

8. RELATED PARTY TRANSACTIONS

State of New Hampshire

The Association collects assessments for the State of New Hampshire. The organizations are financially interrelated as they meet the following criteria:

1. The State of New Hampshire has the ability to influence the Association's operating and financial decisions, primarily through changes in the statute and the State of New Hampshire's annual funding request. This funding request is based on the previous year's actual spending and is not determined by the Association.

2. The State of New Hampshire has an ongoing economic interest in the net assets of the Association. The Association transfers monies to the State of New Hampshire to fund a specified portion of the cost of purchasing vaccines for children in the State of New Hampshire. The Association transferred $22,756,655 and $23,046,587 to the State of New Hampshire in 2026 and 2025, respectively.

Board of Directors

In accordance with RSA 126-Q, the board composition includes three (3) directors who are also employees of assessable entities. There were no direct transactions with the directors and the assessable entities met the same terms and conditions as all other assessable entities.

9. HOUSE BILL 524-FN

As of June 30, 2026, New Hampshire Vaccine Association's governing statute was amended by the Legislature and signed into law by the Governor, effective August 18, 2026. The amendment may affect the accounting and reporting of unexpended New Hampshire Vaccine Association funds held by the State in future reporting periods, if applicable. The amendment had no material effect on the current year's financial statements.

10. SUBSEQUENT EVENTS

In preparing these financial statements, the Association has evaluated events and transactions for potential recognition of disclosure through August 5, 2026, the date the financial statements were available to be issued. Management has determined there are no subsequent events that provide evidence that did not exist at the date of the statement of financial position but arose subsequent to that date which would materially affect the financial position of the Association or cause these financial statements to be misleading to the reader.

11. RECLASSIFICATIONS

Certain amounts and accounts from the prior year's financial statements were reclassified to enhance comparability with the current year's financial statements.

CY2027 Rate Setting

NHVA Audit Committee Meeting
August 19, 2026

Patrick Miller, MPH
Executive Director
pmiller@helmsco.com
603-410-8010

Contents

1. Process
2. Historic Trends and Notable Events
3. NH DHHS Data and NHVA Administrative Budget for Assessment Process
4. Rate Assumptions and Assessment Rate Model

Overview

1. NHVA was created by state statute as a 501(c)(3) with a board representing payers, providers, state agencies, employers, and members of the public. In partnership with NH DHHS and NHID.
2. There are 216 enrolled provider sites and 85+ payers.
3. NH DHHS' FY2027 forecast is $38.1M/year for childhood immunization program with $22.8M (60%) from the insured population vs. VFC funds.
4. NHVA manages the assessment mechanism to raise funds from payers and TPAs to allow the NH DHHS to purchase all childhood immunization via the CDC Price List.
    1. Quarterly Assessments (8/15; 11/15; 2/15; 5/15)
    2. Annual, June Remittance to State Vaccine Purchase Fund (RSA 141-C:17-a)

NHVA New Hampshire Vaccine Association

Roles and Responsibilities

PAYERS

- Remit Assessments

VACCINE ASSOCIATION

- Assessment Rate Setting
- Assessment Management and Compliance
- Funds Sent > State

STATE/CDC

- Provider Network Management
- VFC Compliance
- VTrckS & IIS
- Purchase Immunizations

PROVIDERS

- Order Immunizations
- Administer Immunizations
- Maintain IIS Data

1. Process

NHVA New Hampshire Vaccine Association

Assessment Process Development History

Today

CY2027
- **No Covered Life Growth**
- **Use of Reserves for Rate Reduction**

CY2026
- **No Covered Life Growth**
- **Reserves Strengthened**

CY2025
- **No Covered Life Growth**
- **Includes Nirsevimab (RSV)**
- **Reserves Strengthened**

CY2024
- Covered Lives Stabilized
- DHHS Request Increased
- COVID Costs Included
- Reserves Reevaluated

CY2023
- Year 2 of New Model
- TRICARE Specific Assessments Have Concluded
- Covered Lives Continue to Decline
- DHHS Request Increased
- Lack of Clarity on PHE End Date

CY2022
- Addressed Swings in Payments to NH DHHS
- Addressed Conclusion of TRICARE Specific Assessments
- Simplified Model Back-End Tool

CY2021
- Assumed COVID-19 Covered Lives Adjustment Factors
- Reduced Funds Held by NH DHHS to Zero

CY2020
- Appropriated $5M Reserve Fund
- Accounted for TRICARE Administrative Payment in Model

CY2019
- Helms Simplified Prior Process
- Added TRICARE Lives to Assessment Process
- One Time Administrator Change Costs Absorbed
- Multi-Year Cash Flow / Assessment Rate Model Developed

CY2027 Assessment Rate Setting Process Timeline

☑ = completed milestone
☐ = future milestone

July

- ☑ Data Collection for Actual FY2026 and YTD CY2026
- ☑ Modeling Prep Work Begins

August

- ☑ DHHS Data Received (**8/3**)
- ☑ Modeling Based Upon Trends and Initial NH DHHS data (**8/3-8/12**)
- Today → ☐ Audit Committee Work Session (**8/19**)
- ☐ Modeling Final Assumptions (**8/20-8/27**)

September

- ☐ Audit Committee Work Session (**9/3 if needed**)
- ☐ Review and Approval by Board of Directors (**9/16**)

October

- ☐ Carrier Notification of CY2027 Rate (**10/2**)

2. Historic Trends and Notable Events

Review of FY2026 Notable Fiscal Events

1. Continued Covered Lives Reduction (Slide 10)
2. Immunization Cost Trends (Slide 11-13)
3. ICS Rates and Fixed Investments (Slide 14-15)
4. Unemployment (Slide 16)
5. Medicaid Enrollment (Slide 17)

NHVA New Hampshire Vaccine Association

Declining Assessed Covered Lives Trend and Historic Assessment Rates

Assessment Rate and Total Number of Assessed Child Lives by CY Quarter
Q3 FY2016 - Q3 FY2026
(As of 08.12.2026)



	FY2016 Q3	FY2016 Q4	FY2017 Q1	FY2017 Q2	FY2017 Q3	FY2017 Q4	FY2018 Q1	FY2018 Q2	FY2018 Q3	FY2018 Q4	FY2019 Q1	FY2019 Q2	FY2019 Q3	FY2019 Q4
Total Lives	510,610	508,660	505,958	506,098	504,576	500,008	498,719	499,697	497,824	503,351	502,048	501,056	500,080	497,362
Rate	$9.95	$9.95	$9.95	$9.95	$10.30	$10.30	$10.30	$10.30	$6.70	$6.70	$6.70	$6.70	$6.47	$6.47

	FY2020 Q1	FY2020 Q2	FY2020 Q3	FY2020 Q4	FY2021 Q1	FY2021 Q2	FY2021 Q3	FY2021 Q4	FY2022 Q1	FY2022 Q2	FY2022 Q3	FY2022 Q4	FY2023 Q1	FY2023 Q2
Total Lives	495,606	494,326	495,886	491,513	489,367	484,693	485,499	482,145	481,722	480,433	480,218	477,867	476,691	475,372
Rate	$6.47	$6.47	$6.80	$6.80	$6.80	$6.80	$6.25	$6.25	$6.25	$6.25	$6.85	$6.85	$6.85	$6.85

	FY2023 Q3	FY2023 Q4	FY2024 Q1	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2	FY2026 Q3
Total Lives	480,489	482,532	479,067	481,274	483,195	484,518	480,914	480,001	479,347	475,379	475,604	474,777	475,665
Rate	$8.50	$8.50	$8.50	$8.50	$12.50	$12.50	$12.50	$12.50	$12.75	$12.75	$12.75	$12.75	$13.00

Total Lives — Rate — Poly. (Total Lives)

Source: NHVA

NHVA New Hampshire Vaccine Association

Increasing Immunization Costs



Source: CDC Price List, August 1, 2026

Continued Case for Reserves





Increasing State Vaccine Expenditures with Fund Source Split Stability (State/Payers)



Source: NH DHHS annual spreadsheets; NHVA Historical Data

NHVA New Hampshire Vaccine Association

Cash and Investments (as of August 6, 2026)

1. ICS Rates Have Remained at 354 Basis Points Since March 2026
2. Checking $50,000 + ICS (Cash) $10,016,226 as of 8/6/2026



2. Laddered CD Portfolio at $3,274,458 as of August 7, 2026 with All CDs Coming Due Between 2026-2027; Reserve Targets May Result in Calling CDs Earlier Than Due

Fixed Investments Coming Due



New Hampshire Vaccine Association

US and NH Unemployment Trends



	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25
US	4.2%	4.2%	4.1%	4.1%	4.2%	4.1%	4.0%	4.2%	4.2%	4.2%	4.3%	4.1%
NH	2.6%	2.6%	2.7%	2.8%	2.9%	3.0%	3.0%	3.1%	3.2%	3.2%	3.2%	3.1%

	Jul-25	25-Aug	Sep-25	Oct-25	Nov-25	Dec-25	Jan-26	26-Feb	Mar-26	Apr-26	May-26	Jun-26
US	4.3%	4.3%	4.4%	4.4%	4.5%	4.4%	4.3%	4.4%	4.3%	4.3%	4.3%	4.2%
NH	3.1%	3.1%	3.2%	3.2%	3.2%	3.2%	3.2%	3.2%	3.1%	3.1%	3.0%	2.9%

US NH Poly. (US) Poly. (NH)

NH Medicaid Enrollment



	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26	Mar-26	Apr-26	May-26	Jun-26
Standard Medicaid	125,211	125,377	125,022	125,352	125,727	126,383	126,950	126,782	126,652	126,543	126,450	125,837	125,896	125,180	124,234	123,588	122,180	121,371	120,699	120,174	120,132	120,080	119,046	
Medicaid Expansion	58,969	58,443	58,185	58,155	58,645	59,656	60,117	60,110	59,667	59,539	58,857	58,321	58,162	56,692	55,429	54,525	53,892	53,536	52,435	51,848	51,426	50,828	49,606	
MOM Change - Standard	0.3%	0.1%	-0.3%	0.3%	0.3%	0.5%	0.4%	-0.1%	-0.1%	-0.1%	-0.1%	-0.5%	0.0%	-0.5%	-0.8%	-0.5%	-1.1%	-0.7%	-0.6%	-0.4%	0.0%	0.0%	-0.9%	
MOM Change - Expansion	0.0%	-0.9%	-0.4%	-0.1%	0.8%	1.7%	0.8%	0.0%	-0.7%	-0.2%	-1.1%	-0.9%	-0.3%	-2.8%	-2.2%	-1.6%	-1.2%	-0.7%	-2.1%	-1.1%	-0.8%	-1.2%	-2.4%	

Source: NH DHHS

3. NH DHHS Data and NHVA Administrative Budget for Assessment Process

NHVA New Hampshire Vaccine Association

NH DHHS Tab D Received 08-06-2026 SFY2020-26

						SFY Year End Calcuations to Bring Cash Forward			
			SFY26	SFY25	SFY24	SFY23	SFY22	SFY21	SFY20
		Source	2025/2026	2024/2025	2023/2024	2022/2023	2021/2022	2020/2021	2019/2020
Actual Total exp		4+7	$ 36,416,323.16	$ 37,880,074.54	$ 34,438,650.54	$ 30,094,716.88	$ 29,080,442.34	$ 26,067,468.00	$ 26,126,101.00
VFC	1	CDC Mon Rpt	$ 13,501,068.19	$ 14,557,163.74	$ 14,502,583.19	$ 11,900,982.33	$ 11,493,322.41	$ 10,907,515.00	$ 10,773,619.00
317 - not used for children	2	CDC Mon Rpt	N/A	N/A	N/A	not provided	not provided	not provided	not provided
State Funds (children only)	3	St. Ap(5178-513)	$ 280,385.00	$ 280,354.01	$ 280,337.57	$ 111,150.00	$ 108,251.00	$ 105,300.00	$ 103,178.00
TOTAL GOV'T EXPENDED	4	1+2+3	$ 13,781,453.19	$ 14,837,517.75	$ 14,782,920.76	$ 12,012,132.33	$ 11,601,573.41	$ 11,012,815.00	$ 10,876,797.00
Beginning Balance	5	State Approp	$ 15,149.08	$ 11,118.74	$ 66,848.52	$ 298,504.07	$ -	$ 3,224,124.00	$ 6,722,035.00
Revenue from NHVA*	6	State Approp	$ 22,756,655.19	$ 23,046,587.13	$ 19,600,000.00	$ 17,850,929.00	$ 17,777,373.00	$ 11,830,529.00	$ 11,751,393.00
Vaccine Insurers Expended	7	State Approp	$ 22,634,869.97	$ 23,042,556.79	$ 19,655,729.78	$ 18,082,584.55	$ 17,478,868.93	$ 15,054,653.00	$ 15,249,304.00
Year End Encumbered	8	State Approp	$ 906,545.38	$ 528,429.25	$ 1,581,810.04	$ 128,054.53	$ 298,504.07	$ 3,734,347.00	$ 3,284,045.00
Year End Cash	9	State Approp				$ (66,848.00)	$ 35.10	$ (3,734,347.00)	$ (59,921.00)
TOTAL BAL FORWARD	10	(5+6) -7	$ 136,934.30	$ 15,149.08	$ 11,118.74	$ 66,848.52	$ 298,504.07	$ -	$ 3,224,124.00
CDC Credit (*cash value of inventory at FFY close*)	11	CDC VTrcks	$ 3,646,552.15	$ 2,771,088.12	$ 6,126,235.37	$ 2,068,194.47	$ 1,391,250.00	$ 2,823,837.00	$ 2,804,834.00
Reimbursement from Providers and Excise Tax*	6A	Internal Process	$ 99,614.48	$ 58,112.70	$ 6,458.25	$ -	$ -	$ -	$ -
Added Into This Account									
Note: NHVA as % of total budget			62.16%	60.83%	57.07%	60.09%	60.11%	57.75%	58.37%

Source: From Adriane Burke Program Section Chief 603-271-4261 | on 08/03/2026

* FET credit memo for SFY26	GSK	$ 15,007.50
	Sanofi	$ 1,559.25
	Seqirus	$ 8,882.40
*Reimbursement for SFY26		$ 74,165.33
		$ 99,614.48

NHVA New Hampshire Vaccine Association

NH DHHS Tab D Received 08-06-2026 SFY2013-19

			SFY19	SFY18	SFY17	SFY16	SFY15	SFY14	SFY13
		Source	**2018/2019**	**2017/2018**	**2016/2017**	**2015/2016**	**2014/2015**	**2013/2014**	**2012/2013**
Actual Total exp		4+7	$ 26,837,645.74	$ 26,377,918.00	$ 24,657,418.34	$ 24,741,423.00	$ 26,092,637.01	$ 20,945,468.81	$ 21,918,042.00
VFC	1	CDC Mon Rpt	$ 11,071,713.00	$ 10,329,733.00	$ 11,259,750.00	$ 9,194,539.00	$ 8,570,779.77	$ 8,070,842.51	$ 7,551,690.00
317 - not used for children	2	CDC Mon Rpt	not provided	not provided	not provided	not provided	not provided	not provided	$ 156,375.00
State Funds (children only)	3	St. Ap(5178-513)	$ 273,968.60	$ 293,211.00	$ 392,339.00	$ 302,821.00	$ 206,762.24	$ 460,501.47	$ 482,467.00
TOTAL GOV'T EXPENDED	4	1+2+3	$ 11,345,681.60	$ 10,622,944.00	$ 11,652,089.00	$ 9,497,360.00	$ 8,777,542.01	$ 8,531,343.98	$ 8,190,532.00
Beginning Balance	5	State Approp	$ 12,979,343.00	$ 9,915,171.94	$ 3,267,369.94	$ (1,107,266.17)	$ 3,797,530.83	$ 207,630.66	$ 3,042,623.66
Revenue from NHVA*	6	State Approp	$ 9,234,656.00	$ 18,819,145.00	$ 19,653,132.00	$ 19,618,699.00	$ 12,410,298.00	$ 16,004,025.00	$ 10,892,517.00
Vaccine Insurers Expended	7	State Approp	$ 15,491,964.14	$ 15,754,974.00	$ 13,005,330.00	$ 15,244,062.89	$ 17,315,095.00	$ 12,414,124.83	$ 13,727,510.00
Year End Encumbered	8	State Approp	$ 214,014.00	$ 4,119,258.00	$ 3,912,837.00	$ 5,360,641.11	$ (1,217,018.00)	$ 4,922,399.76	$ 2,278,386.56
Year End Cash	9	State Approp	$ 6,508,021.00	$ 8,860,085.00	$ 6,002,336.00	$ (2,093,270.87)	$ -	$ 1,124,869.00	$ (2,070,755.97)
TOTAL BAL FORWARD	10	(5+6) -7	$ 6,722,034.86	$ 12,979,342.94	$ 9,915,171.94	$ 3,267,369.94	$ (1,107,266.17)	$ 3,797,530.83	$ 207,630.66
CDC Credit (*cash value of inventory at FFY close*)	11	CDC VTrcks	$ 1,856,544.00	$ 4,282,619.00	$ 3,564,068.00	$ 4,377,668.00	not provided	not provided	not provided
Reimbursement from Providers and Excise Tax*	6A	Internal Process	$ -	$ -	$ 19,863.00	$ 13,916.00	$ 37,310.75	$ 29,970.00	$ 119,459.94
Added Into This Account									
Note: NHVA as % of total budget			57.72%	59.73%	52.74%	61.61%	66.36%	59.27%	62.63%

Source: From Adriane Burke Program Section Chief 603-271-4261 | on 08/03/2026

New Hampshire Vaccine Association

NH DHHS Tab C Received 08-06-2026

VFC & STATE Actual Doses for SFY26

VACCINE	SFY2026 Price Per Doses Cost	1st Q TOTAL DOSES	1st Q TOTAL $	2nd Q TOTAL DOSES	2nd Q TOTAL $	3rd Q TOTAL DOSES	3rd Q TOTAL $	Price Effective April 1st, 2026	4th Q TOTAL DOSES	4th Q TOTAL $	SFY26 TOTAL $	SFY26 TOTAL DOSES	5% wastage	Projected Need for SFY 2027 (SFY26+5%)	Roundings	SFY27 Total Projected Cost	Private Price*	
ACTHIB	$ 11.60	1915	$ 22,206.34	1835	$ 21,278.66	1840	$ 21,336.64	$ 12.03	1545	$ 18,586.35	$ 83,407.99	7135	357	7492	6500	$ 78,195.00	$ 13.91	$ 90,428.00
Beyfortus 0.5 RSV	$ 414.75	735	$ 304,841.25	1615	$ 669,821.25	145	$ 60,138.75	$ 443.78	0	$ -	$ 1,034,801.25	2495	125	2620	2600	$ 1,153,833.20	$ 595.06	$ 1,547,161.20
Beyfortus 1.0 RSV	$ 414.75	540	$ 223,965.00	1940	$ 804,615.00	65	$ 26,958.75	$ 443.78	0	$ -	$ 1,055,538.75	2545	127	2672	2700	$ 1,198,211.40	$ 595.06	$ 1,606,667.40
DAPTACEL	$ 22.47	270	$ 6,065.82	200	$ 4,493.20	200	$ 4,493.20	$ 23.28	270	$ 6,284.25	$ 21,336.47	940	47	987	1000	$ 23,275.00	$ 31.52	$ 31,519.00
Enflonsia 105mg RSV	$ 409.75	0	$ -	264	$ 108,174.00	10	$ 4,097.50	$ 422.04	0	$ -	$ 112,271.50	274	14	288	300	$ 126,612.00	$ 556.00	$ 166,800.00
ENGERIX B	$ 17.87	1400	$ 25,023.60	2080	$ 37,177.92	1590	$ 28,419.66	$ 18.39	1710	$ 31,443.48	$ 122,064.66	6780	339	7119	7100	$ 130,554.80	$ 30.11	$ 213,759.70
HAVRIX	$ 24.59	5520	$ 135,709.20	5090	$ 125,137.65	4700	$ 115,549.50	$ 25.30	4940	$ 124,982.00	$ 501,378.35	20250	1013	21263	21300	$ 538,890.00	$ 40.28	$ 857,921.40
HIBERIX	$ 11.36	740	$ 8,408.62	470	$ 5,340.61	810	$ 9,204.03	$ 12.50	650	$ 8,125.00	$ 31,078.26	2670	134	2804	3800	$ 47,500.00	$ 13.54	$ 51,440.60
INFANRIX	$ 22.24	1690	$ 37,585.60	1850	$ 41,144.00	1620	$ 36,028.80	$ 23.04	1580	$ 36,403.20	$ 151,161.60	6740	337	7077	7100	$ 163,584.00	$ 30.69	$ 217,863.50
IPOL	$ 16.90	650	$ 10,986.95	830	$ 14,029.49	380	$ 6,423.14	$ 17.29	390	$ 6,744.27	$ 38,183.85	2250	113	2363	2400	$ 41,503.20	$ 47.81	$ 114,746.40
KINRIX	$ 49.64	2350	$ 116,646.95	2210	$ 109,697.77	1630	$ 80,908.31	$ 51.50	1890	$ 97,338.78	$ 404,591.81	8080	404	8484	8500	$ 437,767.00	$ 65.21	$ 554,319.00
M-M-R II	$ 26.35	3010	$ 79,298.45	2710	$ 71,394.95	2580	$ 67,970.10	$ 26.93	2370	$ 63,816.99	$ 282,480.49	10670	534	11204	9000	$ 242,343.00	$ 97.99	$ 881,910.00
PEDIARIX	$ 67.94	950	$ 64,542.05	530	$ 36,007.67	900	$ 61,145.10	$ 69.87	700	$ 48,905.50	$ 210,600.32	3080	154	3234	3200	$ 223,568.00	$ 111.21	$ 355,872.00
PENTACEL	$ 73.51	1715	$ 126,066.22	1885	$ 138,562.58	1885	$ 138,562.58	$ 78.39	1655	$ 129,738.76	$ 532,930.14	7140	357	7497	7500	$ 587,940.00	$ 130.53	$ 978,975.00
PNEUMOVAX 23	$ 65.80	13	$ 855.40	9	$ 592.20	4	$ 263.20	$ 65.80	0	$ -	$ 1,710.80	26	1	27	100	$ 6,580.00	$ 117.08	$ 11,708.10
PREVNAR 20 TM	$ 192.46	10610	$ 2,042,000.60	9920	$ 1,909,203.20	10330	$ 1,988,111.80	$ 200.13	9440	$ 1,889,227.20	$ 7,828,542.80	40300	2015	42315	42300	$ 8,465,499.00	$ 299.25	$ 12,658,275.00
PRIORIX	$ 26.33	50	$ 1,316.50	110	$ 2,896.30	80	$ 2,106.40	$ 28.23	310	$ 8,751.92	$ 15,071.12	550	28	578	2800	$ 79,049.60	$ 97.99	$ 274,372.00
PROQUAD	$ 186.55	3490	$ 651,059.50	3070	$ 572,708.50	2290	$ 427,199.50	$ 194.95	2880	$ 561,447.36	$ 2,212,414.86	11730	587	12317	12300	$ 2,397,848.10	$ 289.17	$ 3,556,766.40
QUADRACEL	$ 49.70	970	$ 48,210.94	1150	$ 57,157.30	740	$ 36,779.48	$ 51.57	580	$ 29,910.60	$ 172,058.32	3440	172	3612	3600	$ 185,652.00	$ 67.04	$ 241,333.20
RECOMBIVAX HB	$ 15.14	280	$ 4,240.04	130	$ 1,968.59	340	$ 5,148.62	$ 15.86	270	$ 4,282.74	$ 15,639.99	1020	51	1071	1100	$ 17,448.20	$ 29.27	$ 32,191.50
ROTARIX	$ 111.72	2390	$ 267,015.58	2820	$ 315,056.04	2360	$ 263,663.92	$ 114.78	2460	$ 282,348.96	$ 1,128,084.50	10030	502	10532	10500	$ 1,205,148.00	$ 155.80	$ 1,635,858.00
ROTATEQ	$ 84.02	3990	$ 335,231.82	3010	$ 252,894.18	3230	$ 271,378.14	$ 87.35	2710	$ 236,713.08	$ 1,096,217.22	12940	647	13587	13600	$ 1,187,932.80	$ 102.74	$ 1,397,277.60
VAQTA	$ 24.67	410	$ 10,116.34	240	$ 5,921.76	340	$ 8,389.16	$ 25.39	190	$ 4,824.48	$ 29,251.74	1180	59	1239	1200	$ 30,470.40	$ 39.99	$ 47,985.60
VARIVAX	$ 151.45	2900	$ 439,193.40	3010	$ 455,852.46	2440	$ 369,528.24	$ 158.98	2780	$ 441,964.40	$ 1,706,538.50	11130	557	11687	11700	$ 1,860,066.00	$ 192.12	$ 2,247,745.50
VAXELIS	$ 103.76	6150	$ 638,124.00	6260	$ 649,537.60	5800	$ 601,808.00	$ 108.72	5530	$ 601,238.19	$ 2,490,707.79	23740	1187	24927	24900	$ 2,707,202.70	$ 167.36	$ 4,167,264.00
VAXNEUVANCE	$ 175.45	40	$ 7,018.00	20	$ 3,509.00	30	$ 5,263.50	$ 184.19	20	$ 3,683.70	$ 19,474.20	110	6	116	100	$ 18,418.50	$ 240.62	$ 24,062.30
Adolescent																		
ABRYSVO	$ 230.09	0	$ -	0	$ -	0	$ -	$ 240.04	0	$ -	$ -	0	0	0	0	$ -	$ 319.07	$ -
ADACEL 10 PACK	$ 38.06	1000	$ 38,062.00	860	$ 32,733.32	810	$ 30,830.22	$ 39.14	595	$ 22,646.89	$ 124,911.46	3265	163	3428	3400	$ 133,062.40	$ 51.08	$ 173,665.20
ADACEL 5 PACK	$ 38.06	90	$ 3,425.58	150	$ 5,709.30	20	$ 761.24	$ 39.14	10	$ 380.62	$ 10,287.48	270	14	284	300	$ 11,740.80	$ 51.08	$ 15,323.40
BEXSERO	$ 154.50	4250	$ 656,642.00	2770	$ 427,976.08	2830	$ 437,246.32	$ 159.12	2470	$ 381,624.88	$ 1,914,883.39	12320	616	12936	12900	$ 2,052,609.30	$ 251.31	$ 3,241,886.10
BOOSTRIX	$ 38.06	3020	$ 114,944.22	2920	$ 111,138.12	1750	$ 66,606.75	$ 39.14	2420	$ 92,107.62	$ 387,395.79	10110	506	10616	10600	$ 414,831.00	$ 50.14	$ 531,494.60
GARDASIL9	$ 257.07	6850	$ 1,760,936.35	6600	$ 1,696,668.60	4900	$ 1,259,647.90	$ 275.01	4970	$ 1,277,642.87	$ 6,084,067.46	23320	1166	24486	24500	$ 6,737,818.50	$ 329.09	$ 8,062,705.00
JYNNEOS	$ 229.50	0	$ -	0	$ -	0	$ -	$ 232.71	0	$ -	$ -	0	0	0	0	$ -	$ 260.13	$ -
MENQUADFI	$ 114.36	5690	$ 650,708.40	5340	$ 610,682.40	3470	$ 396,829.20	$ 117.77	3540	$ 404,834.40	$ 2,075,118.72	18040	902	18942	18900	$ 2,225,815.20	$ 177.11	$ 3,347,360.10
MENVEO ONE VIAL	$ 111.99	1590	$ 178,057.74	1210	$ 135,503.06	1040	$ 116,465.44	$ 115.32	1280	$ 143,342.08	$ 577,640.96	5120	256	5376	5400	$ 622,749.60	$ 176.71	$ 954,217.80
MENVEO TWO VIAL	$ 111.99	5	$ 559.93	0	$ -	0	$ -	$ 111.99	6	$ 671.92	$ 1,231.85	11	1	12	100	$ 11,198.60	$ 166.75	$ 16,674.80
PENBRAYA	$ 189.35	240	$ 45,444.00	160	$ 30,296.00	170	$ 32,189.50	$ 198.78	110	$ 20,828.50	$ 129,795.30	680	34	714	700	$ 139,146.00	$ 251.86	$ 176,302.00
PenMENVY	$ 189.35	0	$ -	350	$ 66,272.50	180	$ 34,083.00	$ 195.01	790	$ 149,586.50	$ 254,411.82	1320	66	1386	4500	$ 877,536.00	$ 265.75	$ 1,195,875.00
TENIVAC	$ 25.21	22	$ 554.69	15	$ 378.20	1	$ 25.21	$ 26.16	9	$ 226.92	$ 1,193.55	47	2	49	100	$ 2,616.20	$ 45.91	$ 4,591.30
TRUMENBA	$ 142.73	230	$ 32,827.90	110	$ 15,700.30	70	$ 9,991.10	$ 152.67	100	$ 14,273.00	$ 73,786.30	510	26	536	500	$ 76,335.00	$ 225.91	$ 112,955.00
		75765	**$ 9,087,890.98**	**73743**	**$ 9,547,229.76**	**61580**	**$ 7,025,551.90**		**61170**	**$ 7,144,927.40**	**$ 32,932,261.36**	**272258**	**13613**	**285871**	**289100**	**$ 36,460,550.50**		**$ 51,797,272.70**

Influenza Vaccine	PPD	1st Qtr Totals	1st Q $	2nd Qtr Totals	2nd Q $	3rd Qtr Totals	3rd Q $	PPD	4th Qtr Totals	4th Q $	Dist worth this Season VFC and State	TOTAL Doses
Sanofi Fluzone	$ 15.43	12790	$ 197,349.70	17740	$ 273,728.20	4050	$ 62,491.50	$ 16.02	50	$ 771.50	$ 534,340.90	34630
GSK Fluarix	$ 15.22	10560	$ 160,680.96	14330	$ 218,045.28	3620	$ 55,081.92	$ 15.22	140	$ 2,130.24	$ 435,938.40	28650
Flucelvax	$ 22.21	4870	$ 108,143.22	4690	$ 104,146.14	940	$ 20,873.64	$ 28.64	0	$ -	$ 233,163.00	10500
Flumist	$ 20.76	110	$ 2,283.60	180	$ 3,736.80	0	$ -	$ 21.34	0	$ -	$ 6,020.40	290
			$ 468,457.48		$ 599,656.42		$ 138,447.06			$ 2,901.74	**$ 1,209,462.70**	74070

Commited STATE Doses to Purchase-SFY27

Influenza Vaccine	Doses	Amount	Private Price*	
Sanofi Fluzone	24000	$ 384,408.00	$ 20.88	$ 501,072.00
GSK Fluarix	24000	$ 365,184.00	$ 21.08	$ 505,920.00
Flucelvax	8000	$ 229,144.00	$ 43.54	$ 348,336.00
Flumist	100	$ 2,134.00	$ 26.20	$ 2,620.00
	56100	**$ 980,870.00**		**$ 1,357,948.00**

COVID-19 VACCINE	PPD	1st Q Totals	1st Q $	2nd Q Totals	2nd Q $	3rd Q Totals	3rd Q $	PPD	4th Q Totals	4th Q $	Dist worth this Season VFC and State	TOTAL DOSES
COV-19 (Moderna12+)	$ 83.76	0	$ -	2880	$ 241,228.80	520	$ 43,555.20	$ 83.76	210	$ 17,589.60	$ 302,373.60	3610
COV-19(Moderna6m-11y)	$ 78.23	0	$ -	6290	$ 492,066.70	1250	$ 97,787.50	$ 78.23	270	$ 21,122.10	$ 610,976.30	7810
			$ -	9170	$ 733,295.50	1770	$ 141,342.70		480	**$ 38,711.70**	**$ 913,349.90**	**11420**

COVID-19 VACCINE	Book in July	Amount	Private Price*	
COV-19 (Moderna12+)	3000	$ 240,720.00	$ 141.80	$ 425,400.00
COV-19(Moderna6m-11y)	5000	$ 401,200.00	$ 129.00	$ 645,000.00
	8000	**$ 641,920.00**		**$ 1,070,400.00**

TOTAL SFY26 DIST VFC+ STATE
$ 35,055,073.96

Estimated COVID-19 PPD: $80.24, subject to change

TOTAL SFY27 DOSES NEED	TOTAL SFY27 NEED	TOTAL PRIVATE COST SFY27
353200	**$ 38,083,340.50**	**$ 54,225,620.70**

Saving

-29.8%

Actual **TOTAL** **pediatric** doses distributed taken from monthly Spend Plan Report

Advance Purchased Vaccine as of June 30th, 2026	**$ 3,646,552.15**
VFC Estimated (last year) Vaccine Funds Contribution	**$ 18,654,034.70**
Estimated STATE GEN Funds Contribution	**$ 280,385.00**
Estimated cost of vaccine (VFC+STATE)	**$ 38,083,340.50**
NHVA Estimated Cost	**$ 22,850,004.30**
Unspent NHVA revenue from prior SFYs	**$ (136,934.30)**
Estimated NHVA funds needed for SFY27	**$ 22,713,070**

Not part of calculation

NHVA New Hampshire Vaccine Association

NH DHHS Tab C Received 08-06-2026

VFC & STATE Actual Doses for SFY26

VACCINE	SFY2026 Price Per Doses Cost	1st Q TOTAL DOSES	1st Q TOTAL $	2nd Q TOTAL DOSES	2nd Q TOTAL $	3rd Q TOTAL DOSES	3rd Q TOTAL $	Price Effective April 1st, 2026	4th Q TOTAL DOSES	4th Q TOTAL $	SFY26 TOTAL $	SFY26 TOTAL DOSES	5% wastage	Projected Need for SFY 2027 (SFY26+5%)	Roundings	SFY27 Total Projected Cost		Private Price*
		75765	$ 9,087,890.98	73743	$ 9,547,229.76	61580	$ 7,025,551.90		61170	$ 7,144,927.40	$ 32,932,261.36	272258	13613	285871	289100	$ 36,460,550.50		$ 51,797,272.70

Influenza Vaccine	PPD	1st Qtr Totals	1st Q $	2nd Qtr Totals	2nd Q $	3rd Qtr Totals	3rd Q $	PPD	4th Qtr Totals	4th Q $	Dist worth this Season VFC and State	TOTAL Doses
			$ 468,457.48		$ 599,656.42		$ 138,447.06			$ 2,901.74	$ 1,209,462.70	74070

COVID-19 VACCINE	PPD	1st Q Totals	1st Q $	2nd Q Totals	2nd Q $	3rd Q Totals	3rd Q $	PPD	4th Q Totals	4th Q $	Dist worth this Season VFC and State	TOTAL DOSES
			$ -	9170	$ 733,295.50	1770	$ 141,342.70		480	$ 38,711.70	$ 913,349.90	11420

TOTAL SFY26 DIST VFC+ STATE
$ 35,055,073.96

Commited STATE Doses to Purchase-SFY27

Influenza Vaccine	Doses	Amount	Private Price*
	56100	$ 980,870.00	$ 1,357,948.00

COVID-19 VACCINE	Book in July	Amount	Private Price*
	8000	$ 641,920.00	$ 1,070,400.00

Estimated COVID-19 PPD: $80.24, subject to change	TOTAL SFY27 DOSES NEED	TOTAL SFY27 NEED	TOTAL PRIVATE COST SFY27
	353200	$ 38,083,340.50	$ 54,225,620.70
			Saving
			-29.8%

Actual **TOTAL** **pediatric** doses distributed taken from monthly Spend Plan Report

Advance Purchased Vaccine as of June 30th, 2026	$ 3,646,552.15
VFC Estimated (last year) Vaccine Funds Contribution	$ 18,654,034.70
Estimated STATE GEN Funds Contribution	$ 280,385.00
Estimated cost of vaccine (VFC+STATE)	$ 38,083,340.50
NHVA Estimated Cost	$ 22,850,004.30
Unspent NHVA revenue from prior SFYs	$ (136,934.30)
Estimated NHVA funds needed for SFY27	$ 22,713,070

Not part of calculation

Advance Purchased Vaccine as of June 30th, 2026	$ 3,646,552.15
VFC Estimated (last year) Vaccine Funds Contribution	$ 18,654,034.70
Estimated STATE GEN Funds Contribution	$ 280,385.00
Estimated cost of vaccine (VFC+STATE)	$ 38,083,340.50
NHVA Estimated Cost	$ 22,850,004.30
Unspent NHVA revenue from prior SFYs	$ (136,934.30)
Estimated NHVA funds needed for SFY27	$ 22,713,070

NHVA New Hampshire Vaccine Association

FY2027 Administrative Budget – Adopted by Board June 17, 2026

		Jul 26	Aug 26	Sep 26	Oct 26	Nov 26	Dec 26	Jan 27	Feb 27	Mar 27	Apr 27	May 27	Jun 27	FY2027 Budget Total	% Change From Prior Year	FY2026 Budget Total	FY2025 Budget Total
EXPENSE																	
1	**Administrative Fees**	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 129,300	0.0%	$ 129,300	$ 117,552
2	**Subcontractors**																
3	**Subtotal**	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 10,775	$ 129,300	0.0%	$ 129,300	$ 117,552
4	**Bank Fees**																
5	**Board Meeting Expense**	$ -	$ -	$ 990	$ 120	$ 120	$ -	$ 120	$ -	$ 120	$ 95	$ -	$ 120	$ 1,685	0.0%	$ 1,685	$ 1,685
6	**Stationary and Printing**	$ 35	$ 35	$ 35	$ 35	$ 35	$ 35	$ 35	$ 35	$ 35	$ 35	$ 35	$ 35	$ 420	0.0%	$ 420	$ 420
7	**Dues and Subscriptions**																$ -
8	**Insurance (D&O)**							$ 4,000						$ 4,000	-5.9%	$ 4,250	$ 4,250
9	**Licenses and Fees**				$ 75									$ 75	0.0%	$ 75	$ 75
10	**Postage and Shipping**	$ 10	$ 10	$ 10	$ 10	$ 10	$ 10	$ 10	$ 10	$ 10	$ 10	$ 10	$ 10	$ 120	0.0%	$ 120	$ 120
11	**Professional Fees - Audit**		$ 16,100											$ 16,100	3.2%	$ 15,600	$ 10,285
12	**Professional Fees - Legal**	$ 2,083	$ 2,083	$ 2,083	$ 2,083	$ 2,083	$ 2,083	$ 2,083	$ 2,083	$ 2,083	$ 2,083	$ 2,083	$ 2,083	$ 25,000	0.0%	$ 25,000	$ 25,000
13	**Public Information Expense**																$ -
14	**Website**			$ 525										$ 525	0.0%	$ 525	$ 525
15	**Subtotal**	$ 2,128	$ 18,228	$ 3,643	$ 2,323	$ 2,248	$ 2,128	$ 6,248	$ 2,128	$ 2,248	$ 2,223	$ 2,128	$ 2,248	$ 47,925	0.5%	$ 47,675	$ 42,360
TOTAL EXPENSE		**$ 12,903**	**$ 29,003**	**$ 14,418**	**$ 13,098**	**$ 13,023**	**$ 12,903**	**$ 17,023**	**$ 12,903**	**$ 13,023**	**$ 12,998**	**$ 12,903**	**$ 13,023**	**$ 177,225**	**0.1%**	**$ 176,975**	**$ 159,912**

Budget Notes:

Expense Categories Reflect the Plan of Operation's Exhibit C

1. Administrative Fees - Fees will be held level for 5 year period of July 1 2025 to June 30 2030 per contract
2. Subcontractors - In prior years it was a placeholder for any IT system changes (e.g., TRICARE in 2019); none budgeted for FY27
4. Bank Fees - Lockbox was eliminated 01/2020 to reduce expenses and Helms brought it in house
5. Board Meeting Expense - Materials; Sept includes annual Zoom Webinar module - no change
6. Stationary and Printing - Office printing - no change
8. Insurance (D&O) - Reduced by $250
9. Licenses and Fees - SOS NH Annual Report filing fee - No change
10. Postage and Shipping - No change
11. Audit - Increase associated in FY2026 with new audit firm. 3% increase for FY2027.
12. Legal - No change
14. Website - annual hosting fees - No change

For Reference: Former Approved Budgets by FY

FY	Annual Budget	% Change from Prior Year	Actual Expended	Budget to Actual Difference
FY2017	$ 162,072		$ 175,359	8.2%
FY2018	$ 167,600	3.4%	$ 178,953	6.8%
FY2019	$ 320,133	91.0%	$ 388,786	21.4%
FY2020	$ 142,700	-55.4%	$ 127,226	-10.8%
FY2021	$ 146,550	2.7%	$ 125,714	-14.2%
FY2022	$ 148,647	1.4%	$ 136,150	-8.4%
FY2023	$ 151,927	2.2%	$ 134,675	-11.4%
FY2024	$ 155,173	2.1%	$ 154,116	-0.7%
FY2025	$ 159,912	3.1%	$ 160,917	0.6%
FY2026	$ 176,975	10.7%	Year in Progress	
FY2027	$ 177,225	0.1%	Future Period	

Note: FY2026 Annual Expenses Were 13.9% Below Budget at $152,295 Per Draft Audited Financials

4. Rate Assumptions and Assessment Rate Model

Rate Modeling Components



NHVA New Hampshire Vaccine Association

CY2027 Model Rate Assumptions

1. No NHVA funds to recover in June 2027 from NH DHHS
2. Reserves:
   a. 10% reserve of the total non-Federal program cost for the succeeding year (RSA 126-Q:4 II.(c))
   b. $250K administrative reserve
   c. $5M assessment reserve for rate stabilization and absorption of new products
3. The percentage paid by the carriers is 60.0% for FY2027 based on NH DHHS / Federal fund source split
4. Interest rates for cash on hand assume 354bps for ICS and 125bps (net of fees) for remaining CDs
5. Total assessed lives of 475,000 per quarter
6. 4.58% FY2026 projected vaccine cost increase
7. Administrative costs budgeted increase of 2%
8. No late payment assessment interest included
9. $99,614 reimbursement from providers and federal excise tax in FY2026
10. The NHVA's payers benefit from a 29.8% discount from the open market by leveraging CDC pricing through DHHS
11. No new vaccines coming to market

NHVA New Hampshire Vaccine Association

Rate Scenarios for Discussion

- Recommended CY2027 Assessment Rate Drop to $12.00 from $13.00
  - Use a Portion of Reserves to Absorb CDC Rate Inflation
  - Maintain Adequate Reserves
  - Provide 29.8% Discount from CDC Market Price
- CY2027 Assessment Rate Scenarios for Discussion:

Assessment Rate Scenario	CY2027 Rate | FY2027 Remainder Reserves | Ending Cash Balance	CY2028 Rate | FY2028 Remainder Reserves | Ending Cash Balance	CY2029 Rate | FY2029 Remainder Reserves | Ending Cash Balance
Scenario A Flat	**$13.00** | $5.4M | $12.9M	**$13.00** | $6.1M | $13.8M	**$13.00** | $5.0M | $12.9M
Scenario B Decrease	**$12.50** | $5.2M | $12.7M	**$12.50** | $4.9M | $12.6M	**$12.50** | $2.9M | $10.8M
Scenario C Decrease	**$12.00** | $4.9M | $12.5M	**$12.00** | $3.7M | $11.4M	**$12.00** | $0.8M | $8.6M

NHVA New Hampshire Vaccine Association

Discussion Highlights

Model assumptions for discussion in green text

CY2027 Rate Model

(as of Aug 12, 2026)

Expenditures:
FY27 – 4.58%
FY28 – 7.12% ↑
FY29 – 7.12% ↑

Rate:
CY27 - $13.00
CY28 - $13.00
CY29 - $13.00

	For Audit Committee, August 19, 2026 Version 08/12/26	Actual SFY22 2021/2022	Actual SFY23 2022/2023	Actual SFY24 2023/2024	Actual SFY25 2024/2025	Actual SFY26 2025/2026	Forecast SFY27 2026/2027	Forecast SFY28 2027/2028	Forecast SFY29 2028/2029
	ASSUMPTIONS								
1	Average Annual Covered Lives per Quarter	481,130	477,605	481,517	481,195	480,600	475,000	475,000	475,000
2	Assessment Rate	6.25-**6.85**	6.85-8.50	8.50-12.50	12.50-12.75	12.75-13.00	13.00-13.00	13.00-13.00	13.00-13.00
	RESERVES								
4	10% Reserve (RSA 126-Q:4 II.(c))	$ 1,747,887	$ 1,808,259	$ 2,165,998	$ 2,304,256	$ 2,263,487	$ 2,285,000	$ 2,447,734	$ 2,622,058
5	Assessment Reserve	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000
6	Operational Reserve	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000
7	Remainder Reserves	$ 3,632,864	($282,869)	($1,389,711)	$333,786	$2,541,347	$ 5,397,165	$ 6,099,867	$ 5,044,575
	TOTAL EXPENSES	$ 29,080,442	$ 30,094,717	$ 34,438,651	$ 37,880,075	$ 36,416,323	$ 38,083,341	$ 40,795,570	$ 43,700,961
	Percent Change	11.56%	3.49%	14.43%	9.99%	-3.86%	4.58%	7.12%	7.12%
10	**Total NHVA Expended**	$ 17,478,869	$ 18,082,585	$ 19,655,730	$ 23,042,557	$ 22,634,870	$ 22,850,004	$ 24,477,342	$ 26,220,576
	Total NHVA Expended for RSV 2025			N/A					
11	%	60.11%	60.00%	57.07%	60.83%	62.16%	60.00%	60.00%	60.00%
	NHVA OUTFLOWS								
12	Total Distributed by NHVA (June Payment)	$17,777,373	$17,850,929	$19,600,000	$23,046,587	$22,756,655	$ 22,468,552	$ 24,477,342	$ 26,220,576
13	Administrative Expenses	$136,150	$134,675	$154,116	$160,917	$152,295	$155,341	$158,448	$161,617
14	**Total Outflows**	$17,913,523	$17,985,604	$19,754,116	$23,207,504	$22,908,950	$22,623,893	$24,635,790	$26,382,193
	NHVA INFLOWS								
15	Assessments	$12,785,174	$13,879,279	$18,310,143	$24,203,126	$24,311,669	$24,734,580	$24,734,580	$24,734,580
16	Investment Income	($224,867)	$322,083	$694,790	$863,641	$766,645	$766,645	$766,645	$766,645
17	**Total Inflows**	$12,560,307	$14,201,362	$19,004,933	$25,066,767	$25,078,314	$25,501,225	$25,501,225	$25,501,225
18	**NHVA BEGINNING CASH BALANCE**	11,448,477	5,294,329	2,293,531	1,601,553	7,888,042	10,054,834	12,932,166	13,797,601
19	Outflows	17,913,523	17,985,604	19,754,116	23,207,504	22,908,950	22,623,893	24,635,790	26,382,193
20	Inflows	12,560,307	14,201,362	19,004,933	25,066,767	25,078,314	25,501,225	25,501,225	25,501,225
21	Accrual to Cash Items	68,845	(65,339)	80	2,492	(2,572)			
22	Transfer (to)/from Investments	(869,777)		57,125	525,970				
23	To Supplement Assessments								
24	**Ending Cash Balance**	5,294,329	2,293,531	1,601,553	3,989,278	6,786,728	$12,932,166	$13,797,601	$12,916,633
25	**Ending Investment Balance**	5,336,422	4,481,859	4,424,734	3,898,764	3,268,106	0	0	0
		10,630,751	6,775,390	6,026,287	7,888,042	10,054,834	$ 12,932,166	$ 13,797,601	$ 12,916,633
	BALANCE HELD AT STATE								
26	Beginning		$298,504	$66,848	$11,119	$15,149	$136,934	$0	$0
27	Additions/Subtractions	$298,504	($231,656)	($55,729)	$4,030	$121,785	($136,934)	$0	$0
		$298,504	$66,848	$11,119	$15,149	$136,934	$0	$0	$0

NHVA New Hampshire Vaccine Association

Discussion Highlights

Model assumptions for discussion in green text

CY2027 Rate Model

(as of Aug 12, 2026)

Expenditures:
FY27 – 4.58%
FY28 – 7.12% ↑
FY29 – 7.12% ↑

Rate:
CY27 - $12.50
CY28 - $12.50
CY29 - $12.50

For Audit Committee, August 19, 2026
Version 08/12/26

#		Actual SFY22 2021/2022	Actual SFY23 2022/2023	Actual SFY24 2023/2024	Actual SFY25 2024/2025	Actual SFY26 2025/2026	Forecast SFY27 2026/2027	Forecast SFY28 2027/2028	Forecast SFY29 2028/2029
	ASSUMPTIONS								
1	Average Annual Covered Lives per Quarter	481,130	477,605	481,517	481,195	480,600	475,000	475,000	475,000
2	Assessment Rate	6.25-**6.85**	6.85-**8.50**	8.50-12.50	12.50-12.75	12.75-13.00	13.00-12.50	12.00-12.50	13.00-12.50
	RESERVES								
4	10% Reserve (RSA 126-Q:4 II.(c))	$ 1,747,887	$ 1,808,259	$ 2,165,998	$ 2,304,256	$ 2,263,487	$ 2,285,000	$ 2,447,734	$ 2,622,058
5	Assessment Reserve	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000
6	Operational Reserve	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000
7	Remainder Reserves	$ 3,632,864	($282,869)	($1,389,711)	$333,786	$2,541,347	$ 5,159,333	$ 4,910,704	$ 2,904,083
	TOTAL EXPENSES	$ 29,080,442	$ 30,094,717	$ 34,438,651	$ 37,880,075	$ 36,416,323	$ 38,083,341	$ 40,795,570	$ 43,700,961
	Percent Change	11.56%	3.49%	14.43%	9.99%	-3.86%	4.58%	7.12%	7.12%
10	**Total NHVA Expended**	$ 17,478,869	$ 18,082,585	$ 19,655,730	$ 23,042,557	$ 22,634,870	$ 22,850,004	$ 24,477,342	$ 26,220,576
	Total NHVA Expended for RSV 2025			N/A					
11	%	60.11%	60.00%	57.07%	60.83%	62.16%	60.00%	60.00%	60.00%
	NHVA OUTFLOWS								
12	Total Distributed by NHVA (June Payment)	$17,777,373	$17,850,929	$19,600,000	$23,046,587	$22,756,655	$ 22,468,552	$ 24,477,342	$ 26,220,576
13	Administrative Expenses	$136,150	$134,675	$154,116	$160,917	$152,295	$155,341	$158,448	$161,617
14	**Total Outflows**	$17,913,523	$17,985,604	$19,754,116	$23,207,504	$22,908,950	$22,623,893	$24,635,790	$26,382,193
	NHVA INFLOWS								
15	Assessments	$12,785,174	$13,879,279	$18,310,143	$24,203,126	$24,311,669	$24,496,748	$23,783,250	$23,783,250
16	Investment Income	($224,867)	$322,083	$694,790	$863,641	$766,645	$766,645	$766,645	$766,645
17	**Total Inflows**	$12,560,307	$14,201,362	$19,004,933	$25,066,767	$25,078,314	$25,263,393	$24,549,895	$24,549,895
18	**NHVA BEGINNING CASH BALANCE**	11,448,477	5,294,329	2,293,531	1,601,553	7,888,042	10,054,834	12,694,333	12,608,438
19	Outflows	17,913,523	17,985,604	19,754,116	23,207,504	22,908,950	22,623,893	24,635,790	26,382,193
20	Inflows	12,560,307	14,201,362	19,004,933	25,066,767	25,078,314	25,263,393	24,549,895	24,549,895
21	Accrual to Cash Items	68,845	(65,339)	80	2,492	(2,572)			
22	Transfer (to)/from Investments	(869,777)		57,125	525,970				
23	To Supplement Assessments								
24	**Ending Cash Balance**	5,294,329	2,293,531	1,601,553	3,989,278	6,786,728	$12,694,333	$12,608,438	$10,776,140
25	**Ending Investment Balance**	5,336,422	4,481,859	4,424,734	3,898,764	3,268,106	0	0	0
		10,630,751	6,775,390	6,026,287	7,888,042	10,054,834	$ 12,694,333	$ 12,608,438	$ 10,776,140
	BALANCE HELD AT STATE								
26	Beginning		$298,504	$66,848	$11,119	$15,149	$136,934	$0	$0
27	Additions/Subtractions	$298,504	($231,656)	($55,729)	$4,030	$121,785	($136,934)	$0	$0
		$298,504	$66,848	$11,119	$15,149	$136,934	$0	$0	$0

NHVA New Hampshire Vaccine Association

Discussion Highlights

Model assumptions for discussion in green text

CY2027 Rate Model

(as of Aug 12, 2026)

Expenditures:
FY27 – 4.58%
FY28 – 7.12% ↑
FY29 – 7.12% ↑

Rate:
CY27 - $12.00
CY28 - $12.00
CY29 - $12.00

ForAudit Committee, August 19, 2026
Version 08/12/26

#		Actual SFY22 2021/2022	Actual SFY23 2022/2023	Actual SFY24 2023/2024	Actual SFY25 2024/2025	Actual SFY26 2025/2026	Forecast SFY27 2026/2027	Forecast SFY28 2027/2028	Forecast SFY29 2028/2029
	ASSUMPTIONS								
1	Average Annual Covered Lives per Quarter	481,130	477,605	481,517	481,195	480,600	475,000	475,000	475,000
2	Assessment Rate	6.25-**6.85**	6.85-8.50	8.50-12.50	12.50-12.75	12.75-13.00	13.00-12.00	12.00-12.00	13.00-12.00
	RESERVES								
4	10% Reserve (RSA 126-Q:4 II.(c))	$ 1,747,887	$ 1,808,259	$ 2,165,998	$ 2,304,256	$ 2,263,487	$ 2,285,000	$ 2,447,734	$ 2,622,058
5	Assessment Reserve	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 5,000,000
6	Operational Reserve	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000
7	Remainder Reserves	$ 3,632,864	($282,869)	($1,389,711)	$333,786	$2,541,347	$ 4,921,500	$ 3,721,542	$ 763,590
	TOTAL EXPENSES	$ 29,080,442	$ 30,094,717	$ 34,438,651	$ 37,880,075	$ 36,416,323	$ 38,083,341	$ 40,795,570	$ 43,700,961
	Percent Change	11.56%	3.49%	14.43%	9.99%	-3.86%	4.58%	7.12%	7.12%
10	**Total NHVA Expended**	$ 17,478,869	$ 18,082,585	$ 19,655,730	$ 23,042,557	$ 22,634,870	$ 22,850,004	$ 24,477,342	$ 26,220,576
	Total NHVA Expended for RSV 2025			N/A					
11	%	60.11%	60.00%	57.07%	60.83%	62.16%	60.00%	60.00%	60.00%
	NHVA OUTFLOWS								
12	Total Distributed by NHVA (June Payment)	$17,777,373	$17,850,929	$19,600,000	$23,046,587	$22,756,655	$ 22,468,552	$ 24,477,342	$ 26,220,576
13	Administrative Expenses	$136,150	$134,675	$154,116	$160,917	$152,295	$155,341	$158,448	$161,617
14	**Total Outflows**	$17,913,523	$17,985,604	$19,754,116	$23,207,504	$22,908,950	$22,623,893	$24,635,790	$26,382,193
	NHVA INFLOWS								
15	Assessments	$12,785,174	$13,879,279	$18,310,143	$24,203,126	$24,311,669	$24,258,915	$22,831,920	$22,831,920
16	Investment Income	($224,867)	$322,083	$694,790	$863,641	$766,645	$766,645	$766,645	$766,645
17	**Total Inflows**	$12,560,307	$14,201,362	$19,004,933	$25,066,767	$25,078,314	$25,025,560	$23,598,565	$23,598,565
18	**NHVA BEGINNING CASH BALANCE**	11,448,477	5,294,329	2,293,531	1,601,553	7,888,042	10,054,834	12,456,501	11,419,276
19	Outflows	17,913,523	17,985,604	19,754,116	23,207,504	22,908,950	22,623,893	24,635,790	26,382,193
20	Inflows	12,560,307	14,201,362	19,004,933	25,066,767	25,078,314	25,025,560	23,598,565	23,598,565
21	Accrual to Cash Items	68,845	(65,339)	80	2,492	(2,572)			
22	Transfer (to)/from Investments	(869,777)		57,125	525,970				
23	To Supplement Assessments								
24	**Ending Cash Balance**	5,294,329	2,293,531	1,601,553	3,989,278	6,786,728	$12,456,501	$11,419,276	$8,635,648
25	**Ending Investment Balance**	5,336,422	4,481,859	4,424,734	3,898,764	3,268,106	0	0	0
		10,630,751	6,775,390	6,026,287	7,888,042	10,054,834	$ 12,456,501	$ 11,419,276	$ 8,635,648
	BALANCE HELD AT STATE								
26	Beginning		$298,504	$66,848	$11,119	$15,149	$136,934	$0	$0
27	Additions/Subtractions	$298,504	($231,656)	($55,729)	$4,030	$121,785	($136,934)	$0	$0
		$298,504	$66,848	$11,119	$15,149	$136,934	$0	$0	$0

Contact

Patrick Miller, MPH

Executive Director, NHVA

pmiller@helmsco.com

603.225.6633 (o)

Cash Basis

NHVA UNAUDITED
Statement of Cash Flow
Month Ended July 31, 2026

	FY26 - Q1 Actual	FY26 - Q2 Actual	FY26 - Q3 Actual	FY26 - Q4 Actual	FY 2026 YTD Actual	FY 2026 YTD Budget	Difference YTD Act to Budget	FY 2026 Annual Budget
Receipts (Source)								
Assessment Income (Net Refunds)	$ 843,648	$ -	$ -	$ -	$ 843,648	$ 260,000	$ 583,648	$ 24,634,000
* **Accounts Receivable**	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ -
Interest Income - Assessments	$ -	$ -	$ -	$ -	$ -	$ 100	$ (100)	$ 1,870
Interest Income - Bank & Sweep (ICS)	$ 20,515	$ -	$ -	$ -	$ 20,515	$ 15,000	$ 5,515	$ 540,000
Interest Income - Investments	$ 2,634	$ -	$ -	$ -	$ 2,634	$ 4,500	$ (1,866)	$ 55,500
Dividend Income	$ 1,481	$ -	$ -	$ -	$ 1,481	$ 1,000	$ 481	$ 10,900
Accrued Investment Income	$ 649	$ -	$ -	$ -	$ 649	$ 500	$ 149	$ (1,850)
Investment Advisory fees	$ (917)	$ -	$ -	$ -	$ (917)	$ (1,400)	$ 483	$ (16,300)
Realized Gain or Loss	$ 481	$ -	$ -	$ -	$ 481	$ -	$ 481	$ -
Unrecognized Gain or Loss	$ 5,213	$ -	$ -	$ -	$ 5,213	$ 3,500	$ 1,713	$ 145,150
** **Investment - Short term, CDs and Accrual.**	$ (9,541)	$ -	$ -	$ -	$ (9,541)	$ -	$ (9,541)	$ -
	$ 864,163	$ -	$ -	$ -	$ 864,163	$ 283,200	$ 580,963	$ 25,369,270
Disbursements (Use)								
Expenses	$ 11,746	$ -	$ -	$ -	$ 11,746	$ 12,903	$ (1,157)	$ 180,935
* **Prepaids & Accrual Changes**	$ (280)	$ -	$ -	$ -	$ (280)	$ -	$ (280)	$ -
*** **Vaccine Expenses**	$ -	$ -	$ -	$ -	$ -	$ -	$ -	$ 22,713,070
	$ 11,466	$ -	$ -	$ -	$ 11,466	$ 12,903	$ (1,437)	$ 22,894,005
Increase (Decrease)	$ 852,698	$ -	$ -	$ -	$ 852,698	$ 270,297	$ 582,401	$ 2,475,265
Cash Balance - Beginning	$ 6,786,728	$ 7,639,425	$ 7,639,425	$ 7,639,425	$ 6,786,728	$ 6,786,728	$ -	$ 6,786,728
Cash Balance - Ending	$ 7,639,425	$ 7,639,425	$ 7,639,425	$ 7,639,425	$ 7,639,425	$ 7,057,025	$ 582,401	$ 9,261,993

Notes:

* Changes in Balance Sheet accounts are denoted as () = Increases and positive = decrease

** A positive number represents amounts transferred to the ICS account from the Short Term Investments (CDs) account
A negative number represents amounts transferred to the Short Term Investemts (CDs) account from the ICS account

*** Estimated State of NH payment due June 2025

NHVA UNAUDITED
Statement of Financial Position
YTD FY2026 Q1
Month Ended July 31, 2026

	Jun 30, 26	Jul 31, 26	Dec 31, 26	Mar 31, 27	Jun 30, 27
ASSETS	FYE 25	FY26 - Q1	FY26 - Q2	FY26 - Q3	FY26 - Q4
Current Assets	Interim	Interim			
Checking/Savings					
Bank of NH #851031104	$ 50,000	$ 50,000	$ -	$ -	$ -
Bank of NH - ICS	$ 6,736,728	$ 7,589,425	$ -	$ -	$ -
Total Checking/Savings	$ 6,786,728	$ 7,639,425	$ -	$ -	$ -
Accounts Receivable					
Accounts Receivable (A/R)	$ -	$ -	$ -	$ -	$ -
Allowance for Account Receivable	$ -	$ -	$ -	$ -	$ -
Total Accounts Receivable	$ -	$ -	$ -	$ -	$ -
Other Current Assets					
Prepaid Expenses	$ 1,960	$ 1,680	$ -	$ -	$ -
Short Term Investments :					
Short Term Investment - FMV	$ 3,264,697	$ 3,273,590	$ -	$ -	$ -
Accrued Investment Income	$ 3,409	$ 4,058	$ -	$ -	$ -
Total Short Term Investments	$ 3,268,106	$ 3,277,647	$ -	$ -	$ -
Total Other Current Assets	$ 3,270,066	$ 3,279,327	$ -	$ -	$ -
Total Current Assets	$ 10,056,794	$ 10,918,753	$ -	$ -	$ -
TOTAL ASSETS	**$ 10,056,794**	**$ 10,918,753**	**$ -**	**$ -**	**$ -**
LIABILITIES & EQUITY					
Liabilities					
Current Liabilities					
* Accrued Expenses & Deferred Revenue	$ -	$ -	$ -	$ -	$ -
Other Current Liabilities					
Liquidity Reserve	$ 250,000	$ 250,000	$ -	$ -	$ -
Total Current Liabilities	$ 250,000	$ 250,000	$ -	$ -	$ -
Total Liabilities	$ 250,000	$ 250,000	$ -	$ -	$ -
Equity					
Retained Earnings	$ 5,791,400	$ 7,960,765	$ -	$ -	$ -
Fund Balance to be Distributed	$ 1,846,029	$ 1,846,029	$ -	$ -	$ -
Net Income	$ 2,169,365	$ 861,959	$ -	$ -	$ -
Total Equity	$ 9,806,794	$ 10,668,753	$ -	$ -	$ -
TOTAL LIABILITIES & EQUITY	**$ 10,056,794**	**$ 10,918,753**	**$ -**	**$ -**	**$ -**

Notes * AP State of New Hampshire Payable (June 2027) **Estimate** **22,713,070**

Cash Basis

NHVA UNAUDITED
Statement of Changes in Net Assets
YTD FY2026 Q1
Month Ended July 31, 2026

	FY26 - Q1 Actual	FY26 - Q2 Actual	FY26 - Q3 Actual	FY26 - Q4 Actual	FY 2026 YTD Actual	FY 2026 YTD Budget	Difference YTD Act to Bud	FY 2026 Annual Budget
Ordinary Income/Expense					Interim			
Income								
Assessment Income	843,648.00	$ -	$ -	$ -	$ 843,648	260,000.00	$ 583,648	$ 24,634,000
Assessment Income - Refund	0.00	$ -	$ -	$ -	$ -	0.00	$ -	$ -
Interest Income - Assessments	0.00	$ -	$ -	$ -	$ -	100.00	$ (100)	$ 1,870
Interest Income - Bank & Sweep (ICS)	20,515.08	$ -	$ -	$ -	$ 20,515	15,000.00	$ 5,515	$ 540,000
Return on Investments :								
Interest Income - Investments	2,633.98	$ -	$ -	$ -	$ 2,634	4,500.00	$ (1,866)	$ 55,500
Dividend Income	1,481.28	$ -	$ -	$ -	$ 1,481	1,000.00	$ 481	$ 10,900
Accrued Investment Inc Earned	649.17	$ -	$ -	$ -	$ 649	500.00	$ 149	$ (1,850)
Investment Advisory fees	-916.60	$ -	$ -	$ -	$ (917)	-1,400.00	$ 483	$ (16,300)
Realized Gain or Loss	480.90	$ -	$ -	$ -	$ 481	0.00	$ 481	$ -
Unrecognized Gain or Loss	5,212.55	$ -	$ -	$ -	$ 5,213	3,500.00	$ 1,713	$ 145,150
Total Return on Investments :	9,541.28	$ -	$ -	$ -	$ 9,541	8,100.00	$ 1,441	$ 193,400
Total Income	873,704.36	$ -	$ -	$ -	$ 873,704	283,200.00	$ 590,504	$ 25,369,270
	873,704.36					283,200.00		
Expenses								
Vaccine - Annual State Payment	0.00	$ -	$ -	$ -	$ -	0.00	$ -	$ 22,713,070
Management Fees	10,775.00	$ -	$ -	$ -	$ 10,775	10,775.00	$ -	$ 129,300
Professional Fees								
Professional Fees - Legal	668.00	$ -	$ -	$ -	$ 668	2,083.00	$ (1,415)	$ 25,000
Professional Fees - Audit	0.00	$ -	$ -	$ -	$ -	0.00	$ -	$ 16,100
Total · Professional Fees	668.00	$ -	$ -	$ -	$ 668	2,083.00	$ (1,415)	$ 41,100
Insurance	280.00	$ -	$ -	$ -	$ 280	0.00	$ 280	$ 4,250
Postage & Printing (Office)	22.53	$ -	$ -	$ -	$ 23	45.00	$ (22)	$ 4,000
Licenses and Fees	0.00	$ -	$ -	$ -	$ -	0.00	$ -	$ 75
Bank Service Charges	0.00	$ -	$ -	$ -	$ -	0.00	$ -	$ -
Website & SubContractors	0.00	$ -	$ -	$ -	$ -	0.00	$ -	$ 525
Board Meetings Expense	0.00	$ -	$ -	$ -	$ -	0.00	$ -	$ 1,685
Total Expenses	11,745.53	$ -	$ -	$ -	$ 11,746	12,903.00	$ (1,157)	$ 22,894,005
Net Ordinary Income	861,958.83	$ -	$ -	$ -	$ 861,959	270,297.00	$ 591,662	$ 2,475,265
Net Income	**861,958.83**	$ -	$ -	$ -	$ 861,959	**270,297.00**	$ 591,662	$ 2,475,265

Collection Data:				
Quarter being collected	SFY26 - Q1	SFY26 - Q2	SFY27 - Q3	SFY27 - Q4
Payment Due Date	08/15/26	11/15/26	02/15/27	05/15/27
Projected Average Monthly Lives	160,000			
Actual Average Monthly Lives	158,500	-	-	-
Avg Lives Variance +(-)	(1,500)			
Approved Assessment Rate	$ 13.00	$	$	$

Audit Committee Chair Statement re: Public Commentary During Meetings

I welcome members of the public. If the Audit Committee has sufficient time to conduct its business, then it is its policy to reserve time later in the meeting for public commentary. This commentary should be limited to matters that are germane to the role of the NH Vaccine Association: namely, the assertion and collection of assessments to fund the non-federal portion of the State's purchase and distribution of vaccines under the federal Vaccines for Children program. The Association is not a policy-setting organization, it has no influence over the State's participation in the federal Vaccines for Children Program, and its role is not to challenge the vaccine program cost estimates provided by the State absent obvious error. Therefore, as Chair of the Audit Committee, I reserve the right to interrupt and end any public commentary that is not germane to the business of this Association.

Lastly, I remind the public that the commentary period is not an interactive session. If you have questions for the Audit Committee or for its executive staff, please do not ask them during the commentary period because we will not respond as this is not an interactive session. Instead, direct them in writing to our Executive Director, Patrick Miller, info@nhvaccine.org, who will respond in the normal course of Association business.

Thank you in advance for adhering to these public commentary guidelines.

Updated 08/2025